Compass Pathways reported 52-week open-label COMP005 data showing an additional COMP360 25 mg dose extended benefit to one year in treatment-resistant depression.

In Phase 3 COMP005, participants randomised to 25 mg who received another dose had an average 13-point MADRS reduction from baseline at Week 52. Among all Part C recipients, 40% to 45% were responders and about 30% were remitters during the six weeks after dosing, with no new safety findings. Compass said its rolling NDA submission is underway.